DOVA News and Press, Dova Pharmaceuticals Inc. From 09/25/19

DURHAM, N.C., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 4:10 p.m. ET in New York, N...

Gainers: Interlink Electronics ( OTCPK:LINK ) +37% . Avadel Pharmaceuticals plc (NASDAQ: AVDL ) +33% . Arotech Corporation (NASDAQ: ARTX ) +31% . Plus Therapeutics (NASDAQ: PSTV ) +25% . Cesca Therapeutics (NASDAQ: KOOL ) +20% . PriceSmart (NASDAQ: PSMT ) +18% . Dova Pharmaceuticals...

Dova Pharmaceuticals ( DOVA +17.4% ) is up on average volume in apparent response to a bullish report from Wedbush centered on lead drug Doptelet (avatrombopag), approved in the U.S. in May 2018 for chronic liver disease (CLD) patients with thrombocytopenia (low blood platelets) who are un...

DURHAM, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President & Chief Executive Officer, will present company overviews at two upcoming investor conferences: H.C. Wainwright 21 st Annual Global Inves...

Acasti Pharma (NASDAQ: ACST ) initiated with Buy rating at B. Riley FBR. More news on: Acasti Pharma Inc., Blueprint Medicines Corporation, Dova Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Dova Pharmaceuticals, Inc. (DOVA) Q2 2019 Earnings Conference Call August 6, 2019 09:00 ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Jason Hoitt - Chief Commercial Officer Conference Call Participants ...

DURHAM, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 2:30 p.m. ET in New York, NY...

DOPTELET ® (avatrombopag) approved by U.S. Food and Drug Administration (FDA) for treatment of chronic immune thrombocytopenia (ITP); commercial launch occurred mid-July DOPTELET approved by European Commission (EC) for treatment of severe thrombocytopenia in patients with chro...

DURHAM, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, August 6, 2019 at 9:00 a.m. ET to discuss second quarter 2019 financial results and recent operational highlights. A question-and-answer session will follow Dova...

Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...